QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”)
(TSXV: GSD), a clinical stage botanical pharmaceutical corporation
focused on developing a unique portfolio of botanical prescription drugs
and cosmeceutical products, announced today that researchers have
published results related to thylakoid extracts resulting from its R&D
program.
Published in the peer-reviewed Journal of Cosmetic Dermatology1
entitled, ‘‘Study of antioxidant properties of thylakoids and
application in UV protection and repair of UV-induced damage’’ the
article describes results from in vitro studies aiming at better
understanding the mechanism of action of thylakoid extracts in relation
to cosmeceutical applications.
Results showed that the thylakoid extracts were not cytotoxic to human
THP-1 cells. Moreover, formulations comprised of 0.1% or 0.01% of
thylakoids in combination with sunscreen provided a synergetic
protection against UV exposure. When mixed with neutral cream, the
thylakoid extracts were able to repair UV damages on tissue engineered
human skin model. The authors concluded that molecules and enzymes
present in thylakoid extracts are involved in protecting and restoring
the harmful effects of UV exposure.
“We are very pleased to announce this scientific publication describing
properties of thylakoid extracts developed by Devonian, of which
R-Spinasome® forms the basis of our cosmeceutical line of products.
Furthermore, the data from the in vitro studies supports that further
research is needed in order to assess other potential cosmeceutical
applications.” says Devonian’s President & CEO, Dr. Andre P. Boulet.
“We believe that science and skincare must intersect to deliver
revolutionary advances in the exciting new world of botanical
cosmeceuticals. R-Spinasome® forms the basis of our recently launched
cosmeceutical line – Purgenesis™ Anti-Aging Care treatment. We are
excited about this publication as it allows us to deliver science-based
innovative skincare and clinically proven formulations chosen by experts
as the daily skincare solution for women and men of all skin types.”
says Sybil Dahan, President of Altius Healthcare Inc, Devonian’s
Commercial division.
About R-Spinasome®
R-Spinasome® complex, is a photosynthetic cell extract composed of
pigments, proteins and lipids extracted from green leaves. The structure
of this complex is critical to its function as an anti-oxidant, enabling
it to capture and dissipate noxious energy generated by Reactive Oxygen
Species (ROS), returning the complex to a state where it is ready to
undergo new activation cycles. It is this dynamism and capacity to
regenerate that provides R-Spinasome® complex with unprecedented, long
lasting anti-oxidant activity. In addition, an independent study
reported that the photosynthetic cell extract protects against
ultraviolet A (UVA) and ultraviolet B (UVB) damages. R-Spinasome® is
patent-protected in Japan, Canada, United States and Europe (#JP
5952261; #CDN 2,699,6765; #US 13/261,472, #EUR 11 768 299.7).
About Purgenesis™ anti-aging treatment
Purgenesis™ Anti-aging treatment has three components: a day cream, a
night cream and an eye cream. These creams contain R-Spinasome®, a
complex that is an active structure with anti-oxidant properties. The
structure of this complex is critical to its function as an
anti-oxidant, enabling it to capture and dissipate noxious energy
generated by Reactive Oxygen Species (ROS), returning the complex to a
state where it is ready to undergo new activation cycles. It is this
dynamism and capacity to regenerate that provides R-Spinasome® with
unprecedented, long-lasting anti-oxidant activity. A clinical study
involving 72 subjects (aged 35-72 years) was conducted to evaluate the
performance of Purgenesis™ Anti-aging product line compared with two
other leading prestige brands over a 28-day period of use. The results
indicate that Purgenesis™ Anti-aging line is significantly superior than
leading prestige brands in terms of its anti-wrinkle, firmness and
hydration effects. Purgenesis™ Anti-aging treatment is patent-protected
in Japan, Canada, United States and Europe (#JP 5952261; #CDN
2,699,6765; #US 13/261,472, #EUR 11 768 299.7). The product has been
recognized by the Canadian Dermatology Association’s Skin Health
Program™.
About Devonian
Devonian Health Group Inc. is a late stage botanical pharmaceutical
corporation with novel therapeutic approaches to targeting unmet medical
needs. Devonian’s core strategy is to develop prescription botanical
drugs from plant materials and algae for the treatment of
inflammatory-autoimmune diseases including but not limited to ulcerative
colitis and atopic dermatitis. Based on a foundation of over 15 years of
research, Devonian’s focus is further supported by a US-FDA set of
regulatory guidelines favouring a more efficient drug development
pathway for prescription botanical drug products over those of
traditional prescription medicines. Devonian is also involved in the
development of high-value cosmeceutical products leveraging the same
proprietary approach employed with their pharmaceutical offerings.
Devonian Health Group Inc. was incorporated in 2013 and is headquartered
in Québec, Canada where it owns a state-of-the art extraction facility
with full traceability ‘from the seed to the pill’. Acquired in 2018,
Altius Healthcare Inc., its commercialization partner, brings
opportunities for further diversification and growth potential. Devonian
is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information, visit www.groupedevonian.com.
About Altius Healthcare Inc.
Based in Concord, Ontario, Altius Healthcare is a specialty
pharmaceutical company with a primary focus of acquiring and
in-licensing safe and innovative medicines and healthcare products
designed to help people of all ages live healthier lives. Altius then
leverages its expertise in the commercialisation activities required to
successfully launch and distribute these medicines in Canada. The team’s
diverse experience and expertise draws from nearly 40 years of
producing, importing, marketing and distributing branded and generic
medicines.
For more information, visit www.altiushealthcare.ca
Reference
St-Pierre A, et al. Study of antioxidant properties of thylakoids and
application in UV protection and repair of UV-induced damage. J Cosmet
Dermatol. 2019; 1-12.
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s
objectives, strategies and businesses that involve risks and
uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on
various estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking statements if
known or unknown risks affect our business, or if our estimates or
assumptions turn out to be inaccurate. Such risks and assumptions
include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical
and dermo-cosmeceutical products, the availability of funds and
resources to pursue R&D projects, the successful and timely completion
of clinical studies, the ability of Devonian to take advantage of
business opportunities in the pharmaceutical and dermo-cosmeceutical
industries, uncertainties related to the regulatory process and general
changes in economic conditions. You will find a more detailed assessment
of the risks that could cause actual events or results to materially
differ from our current expectations in Devonian’s prospectus dated
April 21st, 2017 under the heading “Risk Factors” related to
Devonian’s business. As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to
update any forward-looking statement even if new information becomes
available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Contacts
Dr André P. Boulet, PhD
President and Chief Executive Officer
Devonian
Health Group inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com